[1]
Piperi, C.; Adamopoulos, C.; Papavassiliou, A.G. Potential of glycative stress targeting for cancer prevention. Cancer Lett., 2017, 390, 153-159.
[2]
Galì, A.; Mucciardi, G.; Butticè, S.; Subba, E.; D’Amico, C.; Lembo, F.; Magno, C. Correlation between advanced glycation end‐products, lower urinary tract symptoms and bladder dysfunctions in patients with type 2 diabetes mellitus. Low. Urin. Tract Symptoms, 2017, 9(1), 15-20.
[3]
van Dooren, F.E.; Pouwer, F.; Schalkwijk, C.G.; Sep, S.J.; Stehouwer, C.D.; Henry, R.M.; Dagnelie, P.C.; Schaper, N.C.; van der Kallen, C.J.; Koster, A.; Denollet, J.; Verhey, F.R.; Schram, M.T. Advanced glycation end product (age) accumulation in the skin is associated with depression: the maastricht study. Depress. Anxiety, 2017, 34(1), 59-67.
[4]
Kim, Y.; Kim, C.; Son, S.M.; Song, H.; Hong, H.S.; Han, S.H.; Mook-Jung, I. The novel RAGE interactor PRAK is associated with autophagy signaling in Alzheimer’s disease pathogenesis. Mol. Neurodegener., 2016, 11(1), 4.
[5]
Prasad, K.; Tiwari, S. Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease. Curr. Pharm. Des., 2017, 23(6), 937-943.
[6]
Sessa, L.; Gatti, E.; Zeni, F.; Antonelli, A.; Catucci, A.; Koch, M.; Pompilio, G.; Fritz, G.; Raucci, A.; Bianchi, M.E. The receptor for advanced glycation end-products (RAGE) is only present in mammals, and belongs to a family of Cell Adhesion Molecules (CAMs). PLoS One, 2014, 9(1), e86903.
[7]
Uribarri, J.; Woodruff, S.; Goodman, S.; Cai, W.; Chen, X.; Pyzik, R.; Yong, A.; Striker, G.E.; Vlassara, H. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J. Am. Diet. Assoc., 2010, 110(6), 911-16.e12.
[8]
Vistoli, G.; De Maddis, D.; Cipak, A.; Zarkovic, N.; Carini, M.; Aldini, G. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): An overview of their mechanisms of formation. Free Radic. Res., 2013, 47(47), 3-27.
[9]
Ahmed, N. Advanced glycation endproducts--role in pathology of diabetic complications. Diabetes Res. Clin. Pract., 2005, 67(1), 3-21.
[10]
Helou, C.; Marier, D.; Jacolot, P.; Abdennebi-Najar, L.; Niquet-Léridon, C.; Tessier, F.J.; Gadonna-Widehem, P. Microorganisms and Maillard reaction products: A review of the literature and recent findings. Amino Acids, 2014, 46(2), 267-277.
[11]
Singh, V.P.; Bali, A.; Singh, N.; Jaggi, A.S. Advanced glycation end products and diabetic complications. Korean J. Physiol. Pharmacol., 2014, 18(1), 1-14.
[12]
Kareb, O.; Gomaa, A.; Champagne, C.P.; Jean, J.; Aïder, M. Electro-activation of sweet defatted whey: Impact on the induced Maillard reaction products and bioactive peptides. Food Chem., 2017, 221, 590-598.
[13]
Szwergold, B.S. Maillard reactions in hyperthermophilic archaea: implications for better understanding of non-enzymatic glycation in biology. Rejuvenation Res., 2013, 16(4), 259-272.
[14]
Nakashima, T.; Ōmura, S.; Takahashi, Y. Generation of superoxide anions by a glycation reaction in conventional laboratory media. J. Biosci. Bioeng., 2012, 114(3), 275-280.
[15]
Gersten, R.A.; Gretebeck, L.M.; Hildick-Smith, G.; Sandwick, R.K. Maillard reaction of ribose 5-phosphate generates superoxide and glycation products for bovine heart cytochrome c reduction. Carbohydr. Res., 2010, 345(17), 2499-2506.
[16]
Choudhary, M.I.; Abbas, G.; Ali, S.; Shuja, S.; Khalid, N.
Khan, K.M. Atta-ur-Rahman; Basha, F.Z. Substituted benzenediol Schiff bases as promising new anti-glycation agents. J. Enzyme Inhib. Med. Chem., 2011, 26(1), 98-103.
[17]
Nawale, R.B.; Mourya, V.K.; Bhise, S.B. Non-enzymatic glycation of proteins: A cause for complications in diabetes. Indian J. Biochem. Biophys., 2006, 43(6), 337-344.
[18]
McCarty, M.F. The low-AGE content of low-fat vegan diets could benefit diabetics - though concurrent taurine supplementation may be needed to minimize endogenous AGE production. Med. Hypotheses, 2005, 64(2), 394-398.
[19]
Koschinsky, T.; He, C.J.; Mitsuhashi, T.; Bucala, R.; Liu, C.; Buenting, C.; Heitmann, K.; Vlassara, H. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc. Natl. Acad. Sci. USA, 1997, 94(12), 6474-6479.
[20]
Gursinsky, T.; Ruhs, S.; Friess, U.; Diabaté, S.; Krug, H.F.; Silber, R.E.; Simm, A. Air pollution-associated fly ash particles induce fibrotic mechanisms in primary fibroblasts. Biol. Chem., 2006, 387(10-11), 1411-1420.
[21]
Peppa, M.; Uribarri, J.; Vlassara, H. Glucose, advanced glycation end products, and diabetes complications: What is new and what works. Clin. Diabetes, 2003, 21(4), 186-187.
[22]
Vlassara, H.; Uribarri, J.; Cai, W.; Striker, G. Advanced glycation end product homeostasis: exogenous oxidants and innate defenses. Ann. N. Y. Acad. Sci., 2008, 1126(1), 46-52.
[23]
Arena, S.; Renzone, G.; D’Ambrosio, C.; Salzano, A.M.; Scaloni, A. Dairy products and the Maillard reaction: A promising future for extensive food characterization by integrated proteomics studies. Food Chem., 2017, 219, 477-489.
[24]
Nankali, M.; Karimi, J.; Goodarzi, M.T.; Saidijam, M.; Khodadadi, I.; Razavi, A.N.E.; Rahimi, F. Increased expression of the Receptor for Advanced Glycation End-products (RAGE) is associated with advanced breast cancer stage. Oncol. Res. Treat., 2016, 39(10), 622-628.
[25]
Sharaf, H.; Matou-Nasri, S.; Wang, Q.; Rabhan, Z.; Al-Eidi, H.; Al Abdulrahman, A.; Ahmed, N. Advanced glycation endproducts increase proliferation, migration and invasion of the breast cancer cell line MDA-MB-231. Biochim. Biophys. Acta, 2015, 1852(3), 429-441.
[26]
Nokin, M.J.; Durieux, F.; Peixoto, P.; Chiavarina, B.; Peulen, O.; Blomme, A.; Turtoi, A.; Costanza, B.; Smargiasso, N.; Baiwir, D.; Scheijen, J.L.; Schalkwijk, C.G.; Leenders, J.; De Tullio, P.; Bianchi, E.; Thiry, M.; Uchida, K.; Spiegel, D.A.; Cochrane, J.R.; Hutton, C.A.; De Pauw, E.; Delvenne, P.; Belpomme, D.; Castronovo, V.; Bellahcène, A. Methylglyoxal, a glycolysis side-product, induces Hsp90 glycation and YAP-mediated tumor growth and metastasis. eLife, 2016, 5, e19375.
[27]
Guo, Y.; Zhang, Y.; Yang, X.; Lu, P.; Yan, X.; Xiao, F.; Zhou, H.; Wen, C.; Shi, M.; Lu, J.; Meng, Q.H. Effects of methylglyoxal and glyoxalase I inhibition on breast cancer cells proliferation, invasion, and apoptosis through modulation of MAPKs, MMP9, and Bcl-2. Cancer Biol. Ther., 2016, 17(2), 169-180.
[28]
Rulli, A.; Carli, L.; Romani, R.; Baroni, T.; Giovannini, E.; Rosi, G.; Talesa, V. Expression of glyoxalase I and II in normal and breast cancer tissues. Breast Cancer Res. Treat., 2001, 66(1), 67-72.
[29]
Al-Maghrebi, M.A.; Al-Mulla, F.; Benov, L.T. Glycolaldehyde induces apoptosis in a human breast cancer cell line. Arch. Biochem. Biophys., 2003, 417(1), 123-127.
[30]
Al-Enezi, K.S.; Alkhalaf, M.; Benov, L.T. Glycolaldehyde induces growth inhibition and oxidative stress in human breast cancer cells. Free Radic. Biol. Med., 2006, 40(7), 1144-1151.
[31]
Flohr, A.M.; Rogalla, P.; Meiboom, M.; Borrmann, L.; Krohn, M.; Thode-Halle, B.; Bullerdiek, J. Variation of HMGB1 expression in breast cancer. Anticancer Res., 2001, 21(6A), 3881-3885.
[32]
Brezniceanu, M.L.; Völp, K.; Bösser, S.; Solbach, C.; Lichter, P.; Joos, S.; Zörnig, M. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J., 2003, 17(10), 1295-1297.
[33]
Nass, N.; Ignatov, A.; Andreas, L.; Weißenborn, C.; Kalinski, T.; Sel, S. Accumulation of the advanced glycation end product carboxymethyl lysine in breast cancer is positively associated with estrogen receptor expression and unfavorable prognosis in estrogen receptor-negative cases. Histochem. Cell Biol., 2017, 147(5), 625-634.
[34]
Feng, L.J.; Liu, H.L.; Tan, Q.; Jin, P. -374T/A polymorphism of the receptor for advanced glycation end products is associated with decreased risk of breast cancer in a Chinese population. Int. J. Clin. Exp. Med., 2015, 8(6), 10109-10113.
[35]
Sharaf, H.; Matou-Nasri, S.; Wang, Q.; Rabhan, Z.; Al-Eidi, H.; Al Abdulrahman, A.; Ahmed, N. Advanced glycation endproducts increase proliferation, migration and invasion of the breast cancer cell line MDA-MB-231. Biochim. Biophys. Acta, 2015, 1852(3), 429-441.
[36]
Lata, K.; Mukherjee, T.K. Knockdown of receptor for advanced glycation end products attenuate 17α-ethinyl-estradiol dependent proliferation and survival of MCF-7 breast cancer cells. Biochim. Biophys. Acta, 2014, 1840(3), 1083-1091.
[37]
Radia, A.M.; Yaser, A.M.; Ma, X.; Zhang, J.; Yang, C.; Dong, Q.; Rong, P.; Ye, B.; Liu, S.; Wang, W. Specific siRNA targeting Receptor for Advanced Glycation End products (RAGE) decreases proliferation in human breast cancer cell lines. Int. J. Mol. Sci., 2013, 14(4), 7959-7978.
[38]
Ishibashi, Y.; Matsui, T.; Takeuchi, M.; Yamagishi, S. Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase. Horm. Metab. Res., 2013, 45(5), 387-390.
[39]
Tesarová, P.; Kalousová, M.; Jáchymová, M.; Mestek, O.; Petruželka, L.; Zima, T. Receptor for advanced glycation end products (RAGE)-soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest., 2007, 25(8), 720-725.
[40]
Dhumale, S.S.; Waghela, B.N.; Pathak, C. Quercetin protects necrotic insult and promotes apoptosis by attenuating the expression of RAGE and its ligand HMGB1 in human breast adenocarcinoma cells. IUBMB Life, 2015, 67(5), 361-373.
[41]
Balendiran, G.K.; Dabur, R.; Fraser, D. The role of glutathione in cancer. Cell Biochem. Funct., 2004, 22(6), 343-352.
[42]
Sheehan, D.; Meade, G.; Foley, V.M.; Dowd, C.A. Structure, function and evolution of glutathione transferases: Implications for classification of non-mammalian members of an ancient enzyme superfamily. Biochem. J., 2001, 360(Pt 1), 1-16.
[43]
Sahin, E.; Göçmen, A.Y.; Koçak, H.; Tuncer, M.; Gümüslü, S. The association of advanced glycation end-products with glutathione status. Ann. Clin. Biochem., 2008, 45(Pt 4), 369-374.
[44]
Deuther-Conrad, W.; Loske, C.; Schinzel, R.; Dringen, R.; Riederer, P.; Münch, G. Advanced glycation endproducts change glutathione redox status in SH-SY5Y human neuroblastoma cells by a hydrogen peroxide dependent mechanism. Neurosci. Lett., 2001, 312(1), 29-32.
[45]
Tang, Y.; Chen, A. Curcumin eliminates the effect of Advanced Glycation End-Products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling. Lab. Invest., 2014, 94(5), 503-516.
[46]
Perry, R.R.; Mazetta, J.A.; Levin, M.; Barranco, S.C. Glutathione levels and variability in breast tumors and normal tissue. Cancer, 1993, 72(3), 783-787.
[47]
Seven, A.; Erbil, Y.; Seven, R.; Inci, F.; Gülyaşar, T.; Barutçu, B.; Candan, G. Breast cancer and benign breast disease patients evaluated in relation to oxidative stress. Cancer Biochem. Biophys., 1998, 16(4), 333-345.
[48]
Sohail, A.; Kanwal, N.; Ali, M.; Sadia, S.; Masood, A.I.; Ali, F.; Iqbal, F.; Crickmore, N.; Shaikh, R.S.; Sayyed, A.H. Effects of glutathione-S-transferase polymorphisms on the risk of breast cancer: A population-based case-control study in Pakistan. Environ. Toxicol. Pharmacol., 2013, 35(2), 143-153.
[49]
Gudmundsdottir, K.; Tryggvadottir, L.; Eyfjord, J.E. GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene. Cancer Epidemiol. Biomarkers Prev., 2001, 10(11), 1169-1173.
[50]
Park, S.K.; Yoo, K.Y.; Lee, S.J.; Kim, S.U.; Ahn, S.H.; Noh, D.Y.; Choe, K.J.; Strickland, P.T.; Hirvonen, A.; Kang, D. Alcohol consumption, glutathione S-transferase M1 and T1 genetic polymorphisms and breast cancer risk. Pharmacogenetics, 2000, 10(4), 301-309.
[51]
Lee, K-M.; Park, S-K.; Kim, S-U.; Doll, M.A.; Yoo, K-Y.; Ahn, S-H.; Noh, D-Y.; Hirvonen, A.; Hein, D.W.; Kang, D. N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer. Cancer Lett., 2003, 196(2), 179-186.
[52]
Chen, X.; Carystinos, G.D.; Batist, G. Potential for selective modulation of glutathione in cancer chemotherapy. Chem. Biol. Interact., 1998, 111-112, 263-275.
[53]
Kondo, T.; Iida, T. [gamma-GCS and glutathione-new molecular targets in cancer treatment] Gan To Kagaku Ryoho, 1997, 24(15), 2219-2225. .
[54]
Bard, S.; Noël, P.; Chauvin, F.; Quash, G. gamma-glutamyltranspeptidase activity in human breast lesions: An unfavourable prognostic sign. Br. J. Cancer, 1986, 53(5), 637-642.
[55]
Matulonis, U.A.; Horowitz, N.S.; Campos, S.M.; Lee, H.; Lee, J.; Krasner, C.N.; Berlin, S.; Roche, M.R.; Duska, L.R.; Pereira, L.; Kendall, D.; Penson, R.T.; Phase, I.I. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J. Clin. Oncol., 2008, 26(35), 5761-5766.
[56]
Montero, A.J.; Diaz-Montero, C.M.; Deutsch, Y.E.; Hurley, J.; Koniaris, L.G.; Rumboldt, T.; Yasir, S.; Jorda, M.; Garret-Mayer, E.; Avisar, E.; Slingerland, J.; Silva, O.; Welsh, C.; Schuhwerk, K.; Seo, P.; Pegram, M.D.; Glück, S. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res. Treat., 2012, 132(1), 215-223.
[57]
Lu, J.; Chew, E-H.; Holmgren, A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc. Natl. Acad. Sci. USA, 2007, 104(30), 12288-12293.
[58]
Lien, E.C.; Lyssiotis, C.A.; Juvekar, A.; Hu, H.; Asara, J.M.; Cantley, L.C.; Toker, A. Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer. Nat. Cell Biol., 2016, 18(5), 572-578.
[59]
Harris, I.S.; Treloar, A.E.; Inoue, S.; Sasaki, M.; Gorrini, C.; Lee, K.C.; Yung, K.Y.; Brenner, D.; Knobbe-Thomsen, C.B.; Cox, M.A.; Elia, A.; Berger, T.; Cescon, D.W.; Adeoye, A.; Brüstle, A.; Molyneux, S.D.; Mason, J.M.; Li, W.Y.; Yamamoto, K.; Wakeham, A.; Berman, H.K.; Khokha, R.; Done, S.J.; Kavanagh, T.J.; Lam, C-W.; Mak, T.W. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell, 2015, 27(2), 211-222.
105
8